A. Darehkordi et al.
Scheme 4
130.2, 140.2, 145.5, 150.5, 154.5, 166.6 (q, 2JCF =35.7 Hz,
C–CF3), 171.8 (C=S) ppm; 19F NMR (470.33 MHz, DMSO-
d6): δ=−73.45 ppm.
were added and the resulting mixture was stirred for 10 min
at room temperature. To the resulting solution, trifuoro-
methylimidoyl chloride (0.5 mmol), thiosemicarbazones
(1 mmol), and potassium carbonate (1 mmol) were added
and then stirred for additional 6 h at 100 °C. Upon comple-
tion, the reaction mixture was cooled to room temperature
then quenched with 10 cm3 saturated sodium thiosulfate
solution. The aqueous layer was extracted with ethyl acetate
(3×15 cm3) and dried over anhydrous magnesium sulfate.
Combined organic layer was concentrated and the residue
was purifed by silica gel column chromatography to aford
the corresponding product.
7‑(4‑Bromophenyl)‑6‑(p‑tolyl)‑5‑(trifuoromethyl)‑2,6‑dihy‑
dro‑3H‑1,2,4,6‑tetrazepine‑3‑thione (C17H12BrF3N4S) Red
1
oil; yield: 78%; IR (KBr): ꢀ
= 3442, 1056 cm−1; H NMR
(500 MHz, DMSO-d6): δ = 2.36 (s, 3H, CH3), 7.33 (bs,
1H, Ar–H), 7.34 (bs, 2H, Ar–H), 7.35 (bs, 1H, NH), 7.36
3
(bs, 1H, Ar–H), 7.47 (d, JHH = 8.3 Hz, 2H, Ar–H), 7.61
3
(d, JHH = 8.3 Hz, 2H, Ar–H) ppm; 13C NMR (125 MHz,
DMSO-d6): δ=21.2 (CH3), 117.3 (q, 1JCF =186.6 Hz, CF3),
124.8, 125.1, 128.0, 130.3, 130.7, 131.2, 132.2, 135.0,
141.1, 149.2 (q, 2JCF =33.9 Hz, C–CF3), 156.3 (C=S) ppm;
19F NMR (470.33 MHz, DMSO-d6): δ=−60.42 ppm.
7‑(4‑Methoxyphenyl)‑6‑(p‑tolyl)‑5‑(trifluorometh‑
yl)‑2,6‑dihydro‑3H‑1,2,4,6‑tetrazepine‑3‑thione (3a,
C18H15F3N4OS) Red oil; yield: 85%; IR (KBr): ꢀ
= 3441,
1
1056 cm−1; H NMR (500 MHz, DMSO-d6): δ = 2.37 (s,
6‑(2‑Chlorophenyl)‑7‑(p‑tolyl)‑5‑(trifuoromethyl)‑2,6‑dihy‑
dro‑3H‑1,2,4,6‑tetrazepine‑3‑thione (C17H12ClF3N4S) Red
3H, CH3), 3.73 (s, 3H, OCH3), 6.93 (d, 3JHH =8.9 Hz, 2H,
Ar–H), 7.34 (d, 3JHH =8.4 Hz, 2H, Ar–H), 7.35 (bs, 1H, NH),
7.36 (d, 3JHH =8.9 Hz, 2H, Ar–H), 7.46 (d, 3JHH =8.4 Hz,
2H, Ar–H) ppm; 13C NMR (125 MHz, DMSO-d6): δ=21.2
(CH3), 55.7 (OCH3), 114.6, 118.0, 123.0 (q, 1JCF =266.4 Hz,
CF3), 128.1, 130.7, 141.0, 145.4, 151.1 (q, 2JCF =35.9 Hz,
C–CF3), 156.9, 161.2, 176.0 (C=S) ppm; 19F NMR
(470.33 MHz, DMSO-d6): δ=−60.39 ppm.
1
oil; yield: 80%; IR (KBr): ꢀ
= 3440, 1057 cm−1; H NMR
(500 MHz, DMSO-d6): δ = 2.36 (s, 3H, CH3), 7.34 (d,
3JHH =8.3 Hz, 2H, Ar–H), 7.43 (d, 3JHH =8.7 Hz, 2H, Ar–H),
7.47 (d, 3JHH =8.7 Hz, 2H, Ar–H), 7.48 (d, 3JHH =8.3 Hz,
2H, Ar–H) ppm; 13C NMR (125 MHz, DMSO-d6): δ=21.2
(CH3), 119.68 (q, 1JCF =223.3 Hz, CF3), 124.8, 128.0, 128.4,
128.6, 129.2, 129.8, 130.3, 130.7, 131.0, 136.0, 141.1, 145.0
(q, 2JCF =37.9 Hz, C–CF3), 156.18 (C=S) ppm; 19F NMR
(470.33 MHz, DMSO-d6): δ=−60.43 ppm.
7‑(4‑Chlorophenyl)‑6‑(p‑tolyl)‑5‑(trifuoromethyl)‑2,6‑dihy‑
dro‑3H‑1,2,4,6‑tetrazepine‑3‑thione (3b, C17H12ClF3N4S) Red
1
oil; yield: 75%; IR (KBr): ꢀ
= 3442, 1056 cm−1; H NMR
6 , 7 ‑ D i ‑ ( p ‑ t o l y l ) ‑ 5 ‑ ( t r i f l u o r o m e t h y l ) ‑ 2 , 6 ‑ d i h y ‑
(500 MHz, DMSO-d6): δ = 2.32 (s, 3H, CH3), 7.22 (d,
dro‑3H‑1,2,4,6‑tetrazepine‑3‑thione (C18H15F3N4S) Red
3
3JHH = 8.1 Hz, 2H, Ar–H), 7.29 (d, JHH = 8.1 Hz, 2H,
oil; yield: 79%; IR (KBr): ꢀ
= 3439, 1055 cm−1 1H
;
Ar–H), 7.69 (d, 3JHH = 8.1 Hz, 4H, Ar–H), 11.36 (bs, 1H,
NH) ppm; 13C NMR (125 MHz, DMSO-d6): δ=21.5 (CH3),
123.7 (q, 1JCF =238.8 Hz, CF3), 126.9, 127.4, 128.8, 129.7,
NMR (500 MHz, DMSO-d6): δ = 2.26 (s, 3H, CH3), 2.36
3
(s, 3H, CH3), 7.17 (d, JHH = 8.0 Hz, 2H, Ar–H), 7.30
1 3